Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04728633 · ClinicalTrials.gov registry record · Phase 2

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

A Phase 2 study of Metastatic Uveal Melanoma and Metastatic Malignant Neoplasm in the Liver, sponsored by Thomas Jefferson University.

Active
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT04728633 is a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Malignant Neoplasm in the Liver that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 28 participants, below the 131-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04728633, a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Malignant Neoplasm in the Liver, is active but no longer recruiting, sponsored by Thomas Jefferson University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.

Interventions

  • OTHER Medical Device Usage and Evaluation
  • DRUG Carmustine
  • PROCEDURE Transarterial Chemoembolization
  • DRUG Ethiodized Oil

Study Locations (1)

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy - Philadelphia

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-09-27
Est. Completion 2027-06-30
Phase Phase 2

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT04728633

The ClinicalTrials.gov registry entry for NCT04728633 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (79% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Medical Device Usage and Evaluation is the first listed.

NCT04728633 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04728633 about?

NCT04728633 is a clinical study titled "Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases". This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (ca...

What is the current status of trial NCT04728633?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-09-27. Estimated completion is 2027-06-30.

What conditions does trial NCT04728633 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8.

What interventions are being tested in trial NCT04728633?

The interventions under investigation include: Medical Device Usage and Evaluation (OTHER), Carmustine (DRUG), Transarterial Chemoembolization (PROCEDURE), Ethiodized Oil (DRUG).

Who is sponsoring clinical trial NCT04728633?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04728633 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.